Citadel Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $351K | Buy |
+77,918
| New | +$351K | ﹤0.01% | 4441 |
|
|
2025
Q1 | – | Sell |
-778,386
| Closed | -$5.4M | – | 6316 |
|
|
2024
Q4 | $5.4M | Sell |
778,386
-380,583
| -33% | -$2.64M | ﹤0.01% | 1737 |
|
|
2024
Q3 | $6.14M | Buy |
1,158,969
+163,026
| +16% | +$864K | ﹤0.01% | 1603 |
|
|
2024
Q2 | $3.72M | Buy |
995,943
+15,704
| +2% | +$58.7K | ﹤0.01% | 1911 |
|
|
2024
Q1 | $6.91M | Sell |
980,239
-3,546
| -0.4% | -$25K | ﹤0.01% | 1532 |
|
|
2023
Q4 | $5.56M | Buy |
983,785
+153,175
| +18% | +$865K | ﹤0.01% | 1580 |
|
|
2023
Q3 | $3.98M | Buy |
830,610
+58,846
| +8% | +$282K | ﹤0.01% | 1811 |
|
|
2023
Q2 | $5.29M | Buy |
771,764
+1,763
| +0.2% | +$12.1K | ﹤0.01% | 1681 |
|
|
2023
Q1 | $6M | Sell |
770,001
-204,194
| -21% | -$1.59M | ﹤0.01% | 1676 |
|
|
2022
Q4 | $7.41M | Buy |
974,195
+21,239
| +2% | +$162K | ﹤0.01% | 1498 |
|
|
2022
Q3 | $7.79M | Buy |
952,956
+833,124
| +695% | +$6.81M | ﹤0.01% | 1463 |
|
|
2022
Q2 | $1.16M | Buy |
119,832
+72,642
| +154% | +$703K | ﹤0.01% | 3252 |
|
|
2022
Q1 | $662K | Sell |
47,190
-2,091
| -4% | -$29.3K | ﹤0.01% | 4155 |
|
|
2021
Q4 | $1.01M | Buy |
49,281
+11,732
| +31% | +$239K | ﹤0.01% | 3827 |
|
|
2021
Q3 | $836K | Sell |
37,549
-58,243
| -61% | -$1.3M | ﹤0.01% | 3969 |
|
|
2021
Q2 | $2.17M | Buy |
+95,792
| New | +$2.17M | ﹤0.01% | 3107 |
|